1. Effects of a thromboxane synthetase inhibitor (OKY-046) and a lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects
- Author
-
Mifune J, Masaki Fujimura, Taga K, Tanaka T, Hifumi S, T. Matsuda, Y. Nakatsumi, Takahashi Y, and F. Sasaki
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Vital capacity ,Bronchi ,Bronchial Provocation Tests ,Thromboxane A2 ,chemistry.chemical_compound ,Oral administration ,Internal medicine ,Benzoquinones ,medicine ,Humans ,Ozagrel ,Aged ,Inhalation ,biology ,business.industry ,Quinones ,Middle Aged ,respiratory system ,medicine.disease ,Acetylcholine ,Asthma ,respiratory tract diseases ,Endocrinology ,Acrylates ,chemistry ,Bronchial hyperresponsiveness ,Enzyme inhibitor ,biology.protein ,Methacrylates ,Female ,business ,Research Article ,medicine.drug - Abstract
The effect of a selective thromboxane synthetase inhibitor, OKY-046, and a selective 5-lipoxygenase inhibitor, AA-861, on bronchial responsiveness to acetylcholine was studied in 23 asthmatic subjects. The provocative concentration of acetylcholine producing a 20% fall in forced expiratory volume in one second (PC20 FEV1) was measured before and after oral administration of OKY-046 (3000 mg over four days) and AA-861 (1100 mg over four days) and inhalation of OKY-046 (30 mg) in 10, 10, and nine asthmatic subjects respectively. Baseline values of FEV1 and forced vital capacity (FVC) were not altered by oral OKY-046, oral AA-861, or inhaled OKY-046. The geometric mean value of PC20 FEV1 increased significantly from 0.55 to 2.24 mg/ml after oral OKY-046, but was unchanged after inhalation of OKY-046 and after oral administration of AA-861. These results suggest that thromboxane A2 may play a part in bronchial hyperresponsiveness to acetylcholine.
- Published
- 1986
- Full Text
- View/download PDF